Tabalumab is a monoclonal antibody directed against B-cell activating factor (BAFF, TNFSF13B). It was being developed as a treatment for autoimmune diseases [1
] and B cell malignancies [2
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence BLAST search using the heavy chain variable region of tabalumab provides 100% match to a sequence claimed in patent US7317089 [3
], and to the antibody with designation 4A5-3.1.1-B4.